Patents by Inventor Anne Simone Josephine Lesage
Anne Simone Josephine Lesage has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9388175Abstract: This invention concerns the use of a compound of formula (I) a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein Z is hydrogen, halo, C1-6alkyl, Het1, HO—C1-6alkyl-, cyano-C1-6alkyl-, amino-C(?O)—C1-6alkyl-, formylamino-C1-6alkyl-, C1-6alkyl-C(?O)—NH—C1-6alkyl-, mono- or di(C1-6alkyl)amino-C(?O)—C1-6alkyl-, phenyl-C1-6alkyl-, or Het4-C1-6alkyl-; Q is phenyl, pyridyl, benzofuranyl, 2,3-dihydro-benzofuranyl, pyrazolyl, isoxazolyl or indazolyl wherein each of said ring systems is optionally being substituted with up to three substituents each independently selected from halo, cyano, C1-6alkyl, C1-6alkyl-O—, C1-6alkylthio, Ar or polyhaloC1-6alkyl; L is phenyl, pyridyl, pyrimidazolyl, 8-Azapyrimidazolyl, pyridazinyl, imidazothiazolyl or furanyl wherein each of said ring systems may optionally be substituted with one or two or more substituents, each substituent independently being selected from halo, hydroxy, amino, cyano, C1-6alkylType: GrantFiled: February 13, 2008Date of Patent: July 12, 2016Assignee: Janssen Pharmaceutica N.V.Inventors: Johannes Wilhelmus John F. Thuring, Gregor James MacDonald, Christopher James Grantham, Theodorus Dinklo, Anne Simone Josephine Lesage
-
Patent number: 8440701Abstract: The present invention relates to substituted 1-(alkyl)-3-aniline-5-aryl triazole derivatives and analogues or pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, according to Formula (I). The invention particularly relates to potent positive allosteric modulators of nicotinic acetylcholine receptors which have the capability of increasing the efficacy of nicotinic receptor agonists.Type: GrantFiled: October 15, 2008Date of Patent: May 14, 2013Assignee: Janssen Pharmaceutica NVInventors: Johannes Wilhelmus John F. Thuring, Theodorus Dinklo, Anne Simone Josephine Lesage, Marcel Frans Leopold De Bruyn, Wei Zhuang
-
Patent number: 8404851Abstract: The present invention relates to 2-[3-(2,2-Difluoro-benzo[1,3]dioxol-5-ylamino)-5-(2,6-dimethyl-pyridin-4-yl)-[1,2,4]triazol-1-yl]-N-ethyl-acetamide and analogues or pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to a potent positive allosteric modulator of nicotinic acetylcholine receptors which have the capability of increasing the efficacy of nicotinic receptor agonists.Type: GrantFiled: October 15, 2008Date of Patent: March 26, 2013Assignee: Janssen Pharmaceutica NVInventors: Johannes Wilhelmus John F. Thuring, Theodorus Dinklo, Anne Simone Josephine Lesage
-
Patent number: 8143419Abstract: The present invention relates to 3-aniline-5-aryl triazole derivatives and analogues or pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, according to Formula (I). The invention particularly relates to positive allosteric modulators of nicotinic acetylcholine receptors, such positive allosteric modulator having the capability to increase the efficacy of nicotinic receptor agonists.Type: GrantFiled: April 19, 2007Date of Patent: March 27, 2012Assignee: Janssen Pharmaceutica N. V.Inventors: Johannes Wilhelmus John F. Thuring, Gregor James MacDonald, Anne Simone Josephine Lesage, Wei Zhuang, Marcel Frans Leopold De Bruyn, Frans Alfons Maria Van Den Keybus, Yves Emiel Maria Van Roosbroeck, Theodorus Dinklo, James Edward Stewart Duffy
-
Publication number: 20110269748Abstract: This invention concerns the use of a compound of formula (I) a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein Z is hydrogen, halo, C1-6alkyl, Het1, HO—C1-6alkyl-, cyano-C1-6alkyl-, amino-C(?O)—C1-6alkyl-, formylamino-C1-6alkyl-, C1-6alkyl-C(?O)—NH—C1-6alkyl-, mono- or di(C1-6alkyl)amino-C(?O)—C1-6alkyl-, phenyl-C1-6alkyl-, or Het4-C1-6alkyl-; Q is phenyl, pyridyl, benzofuranyl, 2,3-dihydro-benzofuranyl, pyrazolyl, isoxazolyl or indazolyl wherein each of said ring systems is optionally being substituted with up to three substituents each independently selected from halo, cyano, C1-6alkyl, C1-6alkyl-O—, C1-6alkylthio, Ar or polyhaloC1-6alkyl; L is phenyl, pyridyl, pyrimidazolyl, 8-Azapyrimidazolyl, pyridazinyl, imidazothiazolyl or furanyl wherein each of said ring systems may optionally be substituted with one or two or more substituents, each substituent independently being selected from halo, hydroxy, amino, cyano, C1-6alkylType: ApplicationFiled: February 13, 2008Publication date: November 3, 2011Inventors: Johannes Wilhelmus John F. Thuring, Gregor James MacDonald, Christopher James Grantham, Theodorus Dinklo, Anne Simone Josephine Lesage
-
Publication number: 20100240707Abstract: The present invention relates to 2-[3-(2,2-Difluoro-benzo[1,3]dioxol-5-ylamino)-5-(2,6-dimethyl-pyridin-4-yl)-[1,2,4]triazol-1-yl]-N-ethyl-acetamide and analogues or pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to a potent positive allosteric modulator of nicotinic acetylcholine receptors which have the capability of increasing the efficacy of nicotinic receptor agonists.Type: ApplicationFiled: October 15, 2008Publication date: September 23, 2010Inventors: Johannes Wilhelmus John F. Thuring, Theodorus Dinklo, Anne Simone Josephine Lesage
-
Publication number: 20100216846Abstract: The present invention relates to substituted 1-(alkyl)-3-aniline-5-aryl triazole derivatives and analogues or pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, according to Formula (I). The invention particularly relates to potent positive allosteric modulators of nicotinic acetylcholine receptors which have the capability of increasing the efficacy of nicotinic receptor agonists.Type: ApplicationFiled: October 15, 2008Publication date: August 26, 2010Inventors: Johannes Wilhelmus John F. Thuring, Theodorus Dinklo, Anne Simone Josephine Lesage, Marcel Frans Leopold De Bruyn, Wei Zhuang
-
Patent number: 7629468Abstract: The present invention concerns compounds of formula. In a preferable embodiment, X represents O; R1 represents C1-6alkyl; cycloC3-12alkyl or (cycloC3-12alkyl)C1-6alkyl, wherein one or more hydrogen atoms in a C1-6alkyl-moiety or in a cycloC3-12alkyl-moiety optionally may be replaced by C1-6alkyloxy, aryl, halo or thienyl; R2 represents hydrogen; halo; C1-6alkyl or amino; R3 and R4 each independently represent hydrogen or C1-6alkyl; or R2 and R3 may be taken together to form —R2—R3—, which represents a bivalent radical of formula -Z4-CH2—CH2—CH2— or -Z4-CH2—CH2— with Z4 being O or NR11 wherein R11 is C1-6alkyl; and wherein each bivalent radical is optionally substituted with C1-6alkyl; or R3 and R4 may be taken together to form a bivalent radical of formula —CH2—CH2—CH2—CH2—; R5 represents hydrogen; Y represents O; and aryl represents phenyl optionally substituted with halo.Type: GrantFiled: May 20, 2005Date of Patent: December 8, 2009Assignee: Janssen Pharmaceutica NVInventors: Dominique Jean-Pierre Mabire, Marc Venet Gaston, Sophie Philippe Coupa, Alain Philippe Poncelet, Anne Simone Josephine Lesage
-
Publication number: 20090253691Abstract: The present invention relates to 3-aniline-5-aryl triazole derivatives and analogues or pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, according to Formula (I). The invention particularly relates to positive allosteric modulators of nicotinic acetylcholine receptors, such positive allosteric modulator having the capability to increase the efficacy of nicotinic receptor agonists.Type: ApplicationFiled: April 19, 2007Publication date: October 8, 2009Applicants: JANSSEN PHARMACEUTICA N.V., BIOFOCUS DPI LIMITEDInventors: Johannes Wilhelmus John F. Thuring, Gregor James MacDonald, Anne Simone Josephine Lesage, Wei Zhuang, Marcel Frans Leopold De Bruyn, Frans Alfons Maria Van Den Keybus, Yves Emiel Maria Van Roosbroeck, Theodorus Dinklo
-
Patent number: 7517517Abstract: The present invention is concerned with radiolabelled quinoline and quinolinone derivatives according Formula (I-A)* or (I-B)* showing metabotropic glutamate receptor antagonistic activity, in particular mGlu1 receptor activity, and their preparation; it further relates to compositions comprising them, as well as their use for marking and identifying metabotropic glutamate receptor sites and for imaging an organ.Type: GrantFiled: March 26, 2003Date of Patent: April 14, 2009Assignee: Janssen Pharmaceutica N.V.Inventors: Anne Simone Josephine Lesage, François Paul Bischoff, Cornelus Gerardus Maria Janssen, Hilde Lavreysen
-
Patent number: 7115630Abstract: The present invention concerns compounds of formula. In a preferable embodiment, X represents O; R1 represents C1-6alkyl; cycloC3-12alkyl or (cycloC3-12alkyl)C1-6alkyl, wherein one or more hydrogen atoms in a C1-6alkyl-moiety or in a cycloC3-12alkyl-moiety optionally may be replaced by C1-6alkyloxy, aryl, halo or thienyl; R2 represents hydrogen; halo; C1-6alkyl or amino; R3 and R4 each independently represent hydrogen or C1-6alkyl; or R2 and R3 may be taken together to form —R2—R3—, which represents a bivalent radical of formula —Z4—CH2—CH2—CH2— or —Z4—CH2—CH2— with Z4 being O or NR11 wherein R11 is C1-6alkyl; and wherein each bivalent radical is optionally substituted with C1-6alkyl; or R3 and R4 may be taken together to form a bivalent radical of formula —CH2—CH2—CH2—CH2—; R5 represents hydrogen; Y represents O; and aryl represents phenyl optionally substituted with halo.Type: GrantFiled: September 25, 2001Date of Patent: October 3, 2006Assignee: Janssen Pharmaceutica N.V.Inventors: Dominique Jean-Pierre Mabire, Marc Gaston Venet, Sophie Coupa, Alain Philippe Poncelet, Anne Simone Josephine Lesage
-
Publication number: 20040082592Abstract: The present invention concerns compounds of formula. In a preferable embodiment, X represents O; R1 represents C1-6alkyl; cycloC3-12alkyl or (cycloC3-12alkyl)C1-6alkyl, wherein one or more hydrogen atoms in a C1-6alkyl-moiety or in a cycloC3-12alkyl-moiety optionally may be replaced by C1-6alkyloxy, aryl, halo or thienyl; R2 represents hydrogen; halo; C1-6alkyl or amino; R3 and R4 each independently represent hydrogen or C1-6alkyl; or R2 and R3 may be taken together to form —R2-R3-, which represents a bivalent radical of formula -Z4-CH2-CH2-CH2- or -Z4-CH2-CH2- with Z4 being O or NR11 wherein R11 is C1-6alkyl; and wherein each bivalent radical is optionally substituted with C1-6alkyl; or R3 and R4 may be taken together to form a bivalent radical of formula —CH2-CH2-CH2-CH2-; R5 represents hydrogen; Y represents O; and aryl represents phenyl optionally substituted with halo.Type: ApplicationFiled: August 14, 2003Publication date: April 29, 2004Inventors: Dominique Jean-Pierre Mabire, Marc Gaston Venet, Sophie Coupa, Alain Philippe Poncelet, Anne Simone Josephine Lesage
-
Patent number: 6075046Abstract: This invention relates to the use of an .alpha.,.alpha.'-iminobis(methylene)bis[2-chromanmethanol] derivative for the manufacture of a medicament for the therapeutic or prophylactic treatment of humans suffering from or prone to degenerative diseases and conditions of the vascular and nervous system which are associated with oxidative stress.Type: GrantFiled: December 21, 1998Date of Patent: June 13, 2000Assignee: Janssen Pharmaceutica, N.V.Inventors: Didier Robert Guy Gabriel de Chaffoy de Courcelles, Anne Simone Josephine Lesage, Josepha Eduarda Maria Francisca Leysen
-
Patent number: 5955485Abstract: The present invention is concerned with the method of using a 2,3-dihydro-imidazo?2,1-b!benzothiazole derivative for the manufacture of a medicament for the therapeutic or prophylactic treatment of humans suffering from ageing of, or degenerative diseases of the nervous and vascular system which are associated with oxidative stress.Type: GrantFiled: August 12, 1997Date of Patent: September 21, 1999Assignee: Janssen Pharmaceutica, N.V.Inventors: Marc Joris De Brabander, Anne Simone Josephine Lesage, Josepha Eduarda Maria Francisca Leysen
-
Patent number: 5874461Abstract: This invention relates to the use of an .alpha.,.alpha.'-iminobs(methylene)bis ?2-chromanmethanol! derivative for the manufacture of a medicament for the therapeutic or prophylactic treatment of humans suffering from or prone to degenerative diseases and conditions of the vascular and nervous system which are associated with oxidative stress.Type: GrantFiled: June 16, 1997Date of Patent: February 23, 1999Assignee: Janssen Pharmaceutica N.V.Inventors: Didier Robert Guy Gabriel de Chaffoy de Courcelles, Anne Simone Josephine Lesage, Josepha Eduarda Maria Francisca Leysen